Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

Sammy Huygens, Quincy Hofsink, Inger S. Nijhof, Abraham Goorhuis, Arnon P. Kater, Peter A.W. Te Boekhorst, Francis Swaneveld, Věra M.J. Novotný, Susanne Bogers, Matthijs R.A. Welkers, Grigorios Papageorgiou, Bart J. Rijnders, Jarom Heijmans

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)
71 Downloads (Pure)

Abstract

BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

Original languageEnglish
Pages (from-to)206-210
Number of pages5
JournalThe Journal of infectious diseases
Volume227
Issue number2
Early online date4 Aug 2022
DOIs
Publication statusPublished - 15 Jan 2023

Bibliographical note

Funding Information:
This work was funded by The Netherlands Organisation for Health Research and Development and an unrestricted grant from Sanquin Blood Supply Foundation. COVIG was provided by the Dutch Ministry of Public Health, Welfare, and Sport. Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Funding to pay the Open Access publication charges for this article was provided by The Netherlands Organisation for Health Research and Development.

Funding Information:
Financial support. This work was funded by The Netherlands Organisation for Health Research and Development and an unrestricted grant from Sanquin Blood Supply Foundation. COVIG was provided by the Dutch Ministry of Public Health, Welfare, and Sport. Funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Funding to pay the Open Access publication charges for this article was provided by The Netherlands Organisation for Health Research and Development.

Publisher Copyright:
© 2022 The Author(s).

Fingerprint

Dive into the research topics of 'Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial'. Together they form a unique fingerprint.

Cite this